Mitchel Hudson and Myla Marshall will be working in Dr. Arnold’s laboratory on the development and evaluation of novel drug development platforms and compounded transdermal formulations.

Ryan Barber will be working with Dr. Riggs in synthesizing new chemical entities for various disease states in conjunction with other PSAS research faculty.

Trey Van Dyke and Stephanie Ard will be working with Dr. Wang on the impact of analogues of anticancer agent B6 on lumacaftor-mediated F508del correction and the functional characterization of NBD1-targeting F508del modulators.

Landon Reeves and Bridget Ivey will be working with Drs. Cropp and Jumbo to determine the effect of PARP inhibition and investigate the effect ATM (Ataxia-Telangiectasia mutated) expression as a genetic modifier of cell growth in a Drosophila melanogaster model. Additionally they will characterize structure activity relationship of PARP inhibitor, talazoparib with the Drosophila melanogaster PARP receptor.

Jillian Walters and Charles Honey will be working in Dr. D’Souza’s laboratory in determining the ability of an herbal adjuvant to stimulate dendritic cells as a novel cancer immunotherapy approach and identifying antigen markers in the S91 melanoma cell line for tumor immunotherapy.

Gracie Giang and Abby Bradley will be working in Dr. Gorman’s laboratory evaluating natural product based adjuvants in the biomodulation of prodrugs for various indications.

Rachel Crane will be working with Drs. Gorman, Arnold and Jumbo on potency evaluations of a new compound class of aromatase inhibitors and optimizing drug delivery of existing therapeutics and in vivo evaluations of prodrug enzyme biomodulators.

Jimice Thomas will be working in Dr. Jumbo’s laboratory where she will explore the mechanism of action of ARBs and Ace inhibitors and the potential benefits of the use of these drugs in the context of neurodegenerative disorders in the Drosophila melanogaster fly model.